FDA Clears Vitamin Shots for Generics, Not a Miracle Cure
Published Date: 11/17/2026
Notice
Summary
The FDA has decided that M.V.I. PEDIATRIC vitamins for injection weren’t taken off the market because they’re unsafe or don’t work. This means drug companies can now apply to make generic versions of these vitamins, helping more kids get access to affordable options. If all rules are followed, these generics could hit the market soon, possibly saving money for families and healthcare providers.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
ANDA pathway opened for generics
The FDA determined that M.V.I. PEDIATRIC for injection was not withdrawn for reasons of safety or effectiveness. Because of that determination, abbreviated new drug applications (ANDAs) that reference this listed drug may be approved if they meet all other legal and regulatory requirements. The listed drug (NDA 018920) was initially approved April 6, 1983, Hospira requested withdrawal and FDA’s withdrawal became effective September 3, 2025, and a citizen petition about this issue was submitted March 4, 2026.
Potential cheaper pediatric vitamin options
Because ANDAs referencing M.V.I. PEDIATRIC may now be approved, drug companies can apply to make generic versions of this pediatric multivitamin injection. If those generics meet requirements and reach the market, parents and healthcare providers could have lower-cost options and greater access to this product.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-23351, Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition
The FDA wants to officially say that N-acetyl-L-cysteine (NAC) can be sold as a dietary supplement. This means companies can legally put NAC in their products without breaking the rules, as long as they follow other laws. People and businesses making or selling supplements with NAC should share their thoughts by January 19, 2027.
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
Previous / Next Documents
Previous: 2026-23366, Determination That M.V.I. ADULT (Multiple Vitamins for Injection) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that M.V.I. ADULT vitamins for injection weren’t taken off the market because they were unsafe or ineffective. This means drug companies can now apply to make generic versions of these vitamins, helping more people get access. No extra safety worries or delays—just a green light for more affordable options soon!
Next: 2026-23368, Notice of Intent To Prepare an Environmental Impact Statement for the Proposed Western Gateway Pipeline Project in Cochise, Graham, Maricopa, and Pinal Counties in Arizona; Chaves, Curry, Doña Ana, Eddy, Grant, Hidalgo, Luna, Otero, and Roosevelt Counties in New Mexico; and Hutchinson, Carson, Potter, Oldham, Deaf Smith, Parmer, Hudspeth, and El Paso Counties in Texas
The Bureau of Land Management is planning a big new pipeline project stretching from Texas to Arizona, passing through parts of Arizona, New Mexico, and Texas. They’re starting an environmental review and want your thoughts by December 17, 2026. This project could change how oil moves across these states and might impact local communities and land.